DrugCite
Search

MOZOBIL

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Mozobil Adverse Events Reported to the FDA Over Time

How are Mozobil adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Mozobil, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Mozobil is flagged as the suspect drug causing the adverse event.

Most Common Mozobil Adverse Events Reported to the FDA

What are the most common Mozobil adverse events reported to the FDA?

Febrile Neutropenia
60 (2.68%)
Nausea
58 (2.59%)
Hypotension
48 (2.14%)
Pneumonia
44 (1.97%)
Sepsis
43 (1.92%)
Pyrexia
41 (1.83%)
Diarrhoea
40 (1.79%)
Respiratory Failure
38 (1.7%)
Thrombocytopenia
33 (1.47%)
Death
31 (1.39%)
Pleural Effusion
31 (1.39%)
Show More Show More
Mucosal Inflammation
30 (1.34%)
Vomiting
30 (1.34%)
Dehydration
29 (1.3%)
Acute Myeloid Leukaemia
26 (1.16%)
Neutropenia
24 (1.07%)
Renal Failure
23 (1.03%)
Dyspnoea
22 (.98%)
Therapeutic Response Decreased
22 (.98%)
Insomnia
21 (.94%)
Ascites
20 (.89%)
Platelet Count Decreased
20 (.89%)
Drug Ineffective
19 (.85%)
Pulmonary Embolism
19 (.85%)
Renal Failure Acute
19 (.85%)
Back Pain
18 (.8%)
Deep Vein Thrombosis
18 (.8%)
Myeloma Recurrence
18 (.8%)
Cystitis Haemorrhagic
17 (.76%)
Dizziness
17 (.76%)
Abdominal Pain
16 (.71%)
Bk Virus Infection
16 (.71%)
Cytomegalovirus Infection
16 (.71%)
Hypoxia
16 (.71%)
Pericardial Effusion
16 (.71%)
Acute Respiratory Distress Syndrome
15 (.67%)
Chills
15 (.67%)
Interstitial Lung Disease
15 (.67%)
Pancytopenia
14 (.63%)
Fatigue
13 (.58%)
Tachycardia
13 (.58%)
Bone Marrow Failure
12 (.54%)
Headache
12 (.54%)
Hyperbilirubinaemia
12 (.54%)
Infection
12 (.54%)
Leukocytosis
12 (.54%)
Acute Graft Versus Host Disease In ...
11 (.49%)
Anxiety
11 (.49%)
Blood Stem Cell Harvest Failure
11 (.49%)
Chest Pain
11 (.49%)
Constipation
11 (.49%)
Convulsion
11 (.49%)
Disease Progression
11 (.49%)
Hyperhidrosis
11 (.49%)
Hypertension
11 (.49%)
Multiple Myeloma
11 (.49%)
Orthostatic Hypotension
11 (.49%)
Procedural Complication
11 (.49%)
Anaemia
10 (.45%)
Aspergillosis
10 (.45%)
Bacterial Sepsis
10 (.45%)
Decreased Appetite
10 (.45%)
Influenza
10 (.45%)
Liver Function Test Abnormal
10 (.45%)
Metastases To Central Nervous Syste...
10 (.45%)
Upper Respiratory Tract Infection
10 (.45%)
Adenovirus Infection
9 (.4%)
Asthenia
9 (.4%)
Gastroenteritis
9 (.4%)
Graft Versus Host Disease
9 (.4%)
Plasmacytoma
9 (.4%)
Pulmonary Alveolar Haemorrhage
9 (.4%)
Splenomegaly
9 (.4%)
Atrial Fibrillation
8 (.36%)
Blood Pressure Fluctuation
8 (.36%)
Bone Pain
8 (.36%)
Bronchopulmonary Aspergillosis
8 (.36%)
Cardiac Amyloidosis
8 (.36%)
Cardiogenic Shock
8 (.36%)
Cognitive Disorder
8 (.36%)
Engraft Failure
8 (.36%)
Generalised Oedema
8 (.36%)
Hallucination
8 (.36%)
Heart Rate Abnormal
8 (.36%)
Hepatic Failure
8 (.36%)
Hypokalaemia
8 (.36%)
Neuropathy Peripheral
8 (.36%)
Oedema Peripheral
8 (.36%)
Pleural Haemorrhage
8 (.36%)
Renal Impairment
8 (.36%)
White Blood Cell Count Increased
8 (.36%)
Acute Graft Versus Host Disease In ...
7 (.31%)
Cerebral Haemorrhage
7 (.31%)
Confusional State
7 (.31%)
Fluid Overload
7 (.31%)
Hypersensitivity
7 (.31%)
Hyponatraemia
7 (.31%)
Malignant Neoplasm Progression
7 (.31%)
Multi-organ Failure
7 (.31%)
Myocardial Infarction
7 (.31%)
Pain
7 (.31%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Mozobil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mozobil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Mozobil

What are the most common Mozobil adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Mozobil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mozobil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Mozobil According to Those Reporting Adverse Events

Why are people taking Mozobil, according to those reporting adverse events to the FDA?

Haematopoietic Stem Cell Mobilisati...
276
Acute Myeloid Leukaemia
111
Multiple Myeloma
45
Non-hodgkins Lymphoma
24
Myelodysplastic Syndrome
20
Chronic Lymphocytic Leukaemia
12
Show More Show More
Lymphoma
11
Acute Lymphocytic Leukaemia
11
Acute Leukaemia
8
Myeloid Leukaemia
7
Bone Marrow Conditioning Regimen
6
Diffuse Large B-cell Lymphoma
6
Chronic Myeloid Leukaemia
5
Hodgkins Disease
4
Germ Cell Cancer
4
Medulloblastoma
4
Testis Cancer
3
Chronic Lymphocytic Leukaemia Trans...
3
Lymphoma Transformation
3
Burkitts Lymphoma
3
Acute Myeloid Leukaemia Recurrent
2
Neuroblastoma
2
Mantle Cell Lymphoma
2
Product Used For Unknown Indication
2
B-cell Lymphoma
2
Rhabdomyosarcoma
1
Renal Amyloidosis
1
Prophylaxis
1
Premedication
1
Non-hodgkins Lymphoma Recurrent
1
Chemotherapy
1
Cytapheresis
1
Recurrent Cancer
1
Nephroblastoma
1
Peripheral Blood Stem Cell Apheresi...
1
Amyloidosis
1

Drug Labels

LabelLabelerEffective
MozobilGenzyme Corporation12-AUG-10

Mozobil Case Reports

What Mozobil safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Mozobil. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Mozobil.